Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.
We have updated our One-pager investment case on Gubra to reflect the Q1 2026 trading statement, the revised CRO guidance, and the clinical newsflow across the pipeline. The quarter has incrementally strengthened the D&P-driven equity value case, while the CRO downgrade has only a limited impact on our valuation framework given the segment's modest share of total enterprise value.
Gubra tiedotti tänään, että sen kumppani Boehringer Ingelheim suunnittelee aloittavansa BI 3034701:n vaiheen 2 kehitystyön vuoden 2026 puolivälissä. BI 3034701 on potentiaalinen luokkansa ensimmäinen kolmois-GLP-1-, GIP- ja NPY2-reseptoriagonisti-peptidi lihavuuden hoitoon, ja se on peräisin Gubran peptidien löytämisalustalta. Lisäksi edistysaskel vahvistaa Gubran alustan ominaisuuksia – erityisesti sen kykyä kehittää erottuvia, luokkansa ensimmäisiä peptidiehdokkaita lihavuuden hoitoon, jotka houkuttelevat jatkuvia kehitysinvestointeja huippuluokan lääkekumppaneilta.
In connection with AbbVie reporting positive topline results from a Phase 1 trial for ABBV-295, Gubra’s out-licensed long-acting amylin analogue, we hosted a live event with CFO Kristian Borbos and IR & Strategy Lead Emma Jappe Lange from Gubra.
On the 9th of March AbbVie reported positive topline results from the multiple ascending dose (MAD) portion of the Phase 1 trial for ABBV-295, Gubra’s out-licensed long-acting amylin analog.
AbbVie today reported positive topline results from the multiple ascending dose (MAD) portion of the Phase 1 trial for ABBV-295, Gubra's out-licensed long-acting amylin analog.
The study demonstrated dose-dependent weight loss ranging from -7.75% to -9.79% at week 12 for weekly dosing cohorts, and -7.86% to -9.73% at week 13 for less frequent dosing regimens (every other week and monthly after week 5), compared to approximately -0.25% for placebo.
